Details

Autor(en) / Beteiligte

• Dietlein, M
• Dressler, J
• Grünwald, F
• Leisner, B
• Moser, E
• Reiners, Chr
• Schicha, H
• Schneider, P
• Schober, O

Titel

Guideline for radioiodine therapy for benign thyroid diseases (version 3)

Ist Teil von

• Nuclear medicine, 2004, Vol.43 (6), p.217-220

Ort / Verlag

Germany

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• The version 3 of the guideline for radioiodine therapy for benign thyroid diseases presents first of all a revision of the version 2. The chapter indication for radioiodine therapy, surgical treatment or antithyroid drugs bases on an interdisciplinary consensus. The manifold criteria for decision making consider the entity of thyroid disease (autonomy, Graves' disease, goitre, goitre recurrence), the thyroid volume, suspicion of malignancy, cystic nodules, risk of surgery and co-morbidity, history of subtotal thyroidectomy, persistent or recurrent thyrotoxicosis caused by Graves' disease including known risk factors for relapse, compression of the trachea caused by goitre, requirement of direct therapeutic effect as well as the patient's preference. Because often some of these criteria are relevant, the guideline offers the necessary flexibility for individual decisions. Further topics are patients' preparation, counseling, dosage concepts, procedural details, results, side effects and follow-up care. The prophylactic use of glucocorticoids during radioiodine therapy in patients without preexisting ophthalmopathy as well as dosage and duration of glucocorticoid medication in patients with preexisting ophthalmopathy need to be clarified in further studies. The pragmatic recommendations for the combined use of radioiodine and glucocorticoids remained unchanged in the 3rd version.